 MONMOUTH JUNCTION, N.J., March 16, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO announces the filing of an Investigational Device Exemption IDE application to conduct the clinical study, Safe and Timely Antithrombotic Removal - Ticagrelor STAR-T, in the United States to support an initial FDA regulatory approval. 